IL6 and COVID-19: Our data show that the combination of IL-6 + AZM + HCQ, resulted in dose-dependent bradycardia, conduction abnormalities, QTc prolongation and cardiac arrest (asystole) but without any episodes of TdP which is consistent, so far, with the clinical data from COVID-19 patients where TdP events are rare3,39.